Published in Gene Therapy Weekly, June 24th, 2004
"Amphiphilic polycationic cyclodextrins, heptakis[2-(omega-amino-oligoethyleneglycol)-6-deoxy-6-hexylthio]-beta-cyclodextrin and heptakis[2-(omega-amino-oligoethyleneglycol)-6-deoxy-6-hexadecylthio]-beta-cyclodextrin, were assessed for condensation of plasmid DNA and cell transfection," scientists writing in the journal STP Pharma Sciences report.
"These cyclodextrins can self-assemble into cationic vesicles or nanoparticles and, unlike their amphiphilic non-aminated analogues, form DNA lipoplexes which efficiently transfected COS-7 cells. Levels of luciferase expression with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-06-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.